Zymeworks To Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on March 2, 2026

Core Insights - Zymeworks Inc. will report its fourth quarter and full year 2025 financial results on March 2, 2026, followed by a conference call and webcast for discussion [1] Company Overview - Zymeworks is a global biotechnology company focused on managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics aimed at improving care for difficult-to-treat diseases such as cancer, inflammation, and autoimmune diseases [2] - The company's strategy includes asset and royalty aggregation to optimize future cash flows from licensed products like Ziihera® (zanidatamab-hrii) and other candidates such as pasritamig [2] - Zymeworks has developed Ziihera, a HER2-targeted bispecific antibody using proprietary Azymetric™ technology, and has exclusive agreements with BeOne Medicines Ltd. and Jazz Pharmaceuticals for its development and commercialization in different territories [2] - The company is advancing a robust pipeline of product candidates, leveraging expertise in antibody drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need [2] - Zymeworks' integrated drug development engine and complementary therapeutic platforms allow for the precise engineering and development of differentiated antibody-based therapeutics, enhanced through strategic partnerships with global biopharmaceutical companies [2]